Clinical algorithms for patients with findings of IgA deficiency when being tested for CD using tTG-IgA levels suggest follow-up serological testing using tissue transglutaminase-immunoglobulin G and/or deaminated gliadin peptide immunoglobulin G, followed by duodenal biopsies [1,3]. This evidence concerns the gene CD79A and selective IgA deficiency disease.